Pharsight

Organon Llc patents expiration

1. Asmanex Hfa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5889015 ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jan, 2014

(10 years ago)

US6365581 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US6057307 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US5889015

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jul, 2014

(9 years ago)

US6057307

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US6365581

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US6068832 ORGANON LLC Chlorofluorocarbon-free mometasone furoate aerosol formulations
Aug, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Aug 12, 2022
Pediatric Exclusivity(PED) Feb 12, 2023

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 12 August, 2019

Treatment: Treatment of asthma

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ASMANEX HFA family patents

Family Patents

2. Asmanex Twisthaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5394868

(Pediatric)

ORGANON LLC Inhalation device for powdered medicaments
Dec, 2012

(11 years ago)

US6057307 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US5889015 ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jan, 2014

(10 years ago)

US6949532 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US6677322 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US6365581 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US5889015

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jul, 2014

(9 years ago)

US6365581

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US6677322

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US6949532

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US6057307

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US5687710 ORGANON LLC Inhaler for powdered medications having spiral deagglomeration chamber
Nov, 2014

(9 years ago)

US5687710

(Pediatric)

ORGANON LLC Inhaler for powdered medications having spiral deagglomeration chamber
May, 2015

(9 years ago)

US5829434 ORGANON LLC Inhaler for powdered medications
Nov, 2015

(8 years ago)

US5829434

(Pediatric)

ORGANON LLC Inhaler for powdered medications
May, 2016

(8 years ago)

US6240918 ORGANON LLC Powdered medication inhaler
Feb, 2017

(7 years ago)

US6240918

(Pediatric)

ORGANON LLC Powdered medication inhaler
Aug, 2017

(6 years ago)

US8173172 ORGANON LLC Preparation of powder agglomerates
Mar, 2018

(6 years ago)

US6503537 ORGANON LLC Preparation of powder agglomerates
Mar, 2018

(6 years ago)

US6503537

(Pediatric)

ORGANON LLC Preparation of powder agglomerates
Sep, 2018

(5 years ago)

US8173172

(Pediatric)

ORGANON LLC Preparation of powder agglomerates
Sep, 2018

(5 years ago)

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 01 February, 2008

Treatment: Treatment of asthma

Dosage: POWDER;INHALATION

More Information on Dosage

ASMANEX TWISTHALER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Clarinex-d 12 Hour patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214684 ORGANON LLC Methods for the treatment of allergic rhinitis
Dec, 2014

(9 years ago)

US7214683 ORGANON LLC Compositions of descarboethoxyloratadine
Dec, 2014

(9 years ago)

US7214684

(Pediatric)

ORGANON LLC Methods for the treatment of allergic rhinitis
Jun, 2015

(8 years ago)

US7214683

(Pediatric)

ORGANON LLC Compositions of descarboethoxyloratadine
Jun, 2015

(8 years ago)

US6100274 ORGANON LLC 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Jul, 2019

(4 years ago)

US6100274

(Pediatric)

ORGANON LLC 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Jan, 2020

(4 years ago)

US7618649 ORGANON LLC Extended release oral dosage composition
Dec, 2020

(3 years ago)

US8187630 ORGANON LLC Extended release oral dosage composition
Dec, 2020

(3 years ago)

US6709676 ORGANON LLC Extended release oral dosage composition
Feb, 2021

(3 years ago)

US7618649

(Pediatric)

ORGANON LLC Extended release oral dosage composition
Jun, 2021

(2 years ago)

Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient

Market Authorisation Date: 01 February, 2006

Treatment: Treatment of allergic rhinitis; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis; Allergic rhinitis

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CLARINEX-D 12 HOUR before it's drug patent expiration?
More Information on Dosage

CLARINEX-D 12 HOUR family patents

Family Patents

4. Dulera patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6057307 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US5889015 ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jan, 2014

(10 years ago)

US6677323 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US6057307

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US5889015

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jul, 2014

(9 years ago)

US6068832 ORGANON LLC Chlorofluorocarbon-free mometasone furoate aerosol formulations
Aug, 2017

(6 years ago)

US7566705 ORGANON LLC Combination of formoterol and mometasone furoate for asthma
May, 2020

(4 years ago)

US7067502 ORGANON LLC Combinations of formoterol and mometasone furoate for asthma
May, 2020

(4 years ago)

US7067502

(Pediatric)

ORGANON LLC Combinations of formoterol and mometasone furoate for asthma
Nov, 2020

(3 years ago)

US7566705

(Pediatric)

ORGANON LLC Combination of formoterol and mometasone furoate for asthma
Nov, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-214) Dec 20, 2020
New Strength(NS) Aug 12, 2022
Pediatric Exclusivity(PED) Jun 20, 2021
New Combination(NC) Jun 22, 2013

Drugs and Companies using FORMOTEROL FUMARATE; MOMETASONE FUROATE ingredient

Market Authorisation Date: 12 August, 2019

Treatment: Treatment of asthma

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

DULERA family patents

Family Patents

5. Fosamax Plus D patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5358941 ORGANON LLC Dry mix formulation for bisphosphonic acids with lactose
Dec, 2012

(11 years ago)

US5681590 ORGANON LLC Dry mix formulation for bisphosphonic acids
Dec, 2012

(11 years ago)

US6090410 ORGANON LLC Dry mix formulation for bisphosphonic acids
Dec, 2012

(11 years ago)

US5681590

(Pediatric)

ORGANON LLC Dry mix formulation for bisphosphonic acids
Jun, 2013

(10 years ago)

US5358941

(Pediatric)

ORGANON LLC Dry mix formulation for bisphosphonic acids with lactose
Jun, 2013

(10 years ago)

US6090410

(Pediatric)

ORGANON LLC Dry mix formulation for bisphosphonic acids
Jun, 2013

(10 years ago)

US5994329 ORGANON LLC Method for inhibiting bone resorption
Jul, 2018

(5 years ago)

US5994329

(Pediatric)

ORGANON LLC Method for inhibiting bone resorption
Jan, 2019

(5 years ago)

Drugs and Companies using ALENDRONATE SODIUM; CHOLECALCIFEROL ingredient

Market Authorisation Date: 07 April, 2005

Treatment: Treatment of osteoporosis in post menopausal women and/or the treatment to increase bone mass in men with osteoporosis

Dosage: TABLET;ORAL

How can I launch a generic of FOSAMAX PLUS D before it's drug patent expiration?
More Information on Dosage

FOSAMAX PLUS D family patents

Family Patents

6. Maxalt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5602162

(Pediatric)

ORGANON LLC Imidazole, triazole and tetrazole derivatives
Jul, 2012

(11 years ago)

US5298520

(Pediatric)

ORGANON LLC Triazole containing indole derivatives
Dec, 2012

(11 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jun 16, 2015
New Patient Population(NPP) Dec 16, 2014

Drugs and Companies using RIZATRIPTAN BENZOATE ingredient

Market Authorisation Date: 29 June, 1998

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of MAXALT before it's drug patent expiration?
More Information on Dosage

MAXALT family patents

Family Patents

7. Nasonex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6723713 ORGANON LLC Use of mometasone furoate for treating upper airway diseases
Jan, 2014

(10 years ago)

US5837699 ORGANON LLC Use of mometasone furoate for treating upper airway passage diseases
Jan, 2014

(10 years ago)

US5837699

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating upper airway passage diseases
Jul, 2014

(9 years ago)

US6723713

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating upper airway diseases
Jul, 2014

(9 years ago)

US6127353 ORGANON LLC Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
Oct, 2017

(6 years ago)

US6127353

(Pediatric)

ORGANON LLC Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
Apr, 2018

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-99) Jan 19, 2014
New Indication(I-626) May 26, 2013

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 01 October, 1997

Treatment: Allergic rhinitis or nasal polyps

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of NASONEX before it's drug patent expiration?
More Information on Dosage

NASONEX family patents

Family Patents

8. Xaciato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129896 ORGANON LLC Topical formulations and treatments
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 07, 2024
Generating Antibiotic Incentives Now(GAIN) Dec 07, 2029

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 07 December, 2021

Treatment: Method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation

Dosage: GEL;VAGINAL

More Information on Dosage

XACIATO family patents

Family Patents